A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Phase 2

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive

• Registration Number: NCT00482235
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-12
• Primary Completion: 2003-04
• Study Completion: 2003-04
• Study First Submitted: 2007-06-01
• Study First Submitted QC: 2007-06-01
• Study First Posted: 2007-06-05
• Status Verified: 2015-11
• Last Update Submitted: 2015-11-30
• Last Update Posted: 2015-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• You are between the ages of 40 and 75
• You have had a history for at least a year of COPD symptoms
• You have a history of smoking one pack of cigarettes per day for 10 years

Exclusion Criteria

• You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
• You have donated blood in the last 4 weeks.
• You have been hospitalized or had major surgery in the last 4 weeks
• You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
• You have a history of heart problems in the last 6 months
• You have a history of stomach problems
• You are unwilling to avoid grapefruit juice throughout the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL